AAPG vs TSHA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
AAPG · Ascentage Pharma$11.97 ▼ 3.78%
TSHA · Taysha Gene Therapies$3.72 ▼ 1.33%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- AAPG -62.6%
- TSHA -15.8%
Head to head
| Metric | AAPG | TSHA |
|---|---|---|
| Price | $11.97 | $3.72 |
| Change today | ▼ 3.78% | ▼ 1.33% |
| Market cap | $1.12B | $1.21B |
| Return, 3 months | -28.4% | -37.7% |
| Return, year to date | -54.4% | -32.4% |
| Return, 1 year | -60.9% | -11.2% |
| P/E (TTM) | – | – |
| P/B | 13.4 | 3.4 |
| P/E percentile vs own 5y | 98th | 22nd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -41.5% | -100.0% |
| Net profit growth (YoY) | -206.4% | -73.5% |
| Gross margin | 93.9% | – |
| Operating margin | -216.7% | -2,854.9% |
| Net margin | -228.5% | -2,728.0% |
| Return on equity | -240.3% | -47.1% |
| Analyst target vs. price | +250.9% | +285.2% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 29 | 35 |
| 30-day volatility | 64.7% | 74.4% |
| Max drawdown, 1 year | -65.1% | -49.7% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TSHA is the largest of the group by market value.
- TSHA has returned the most over the past year.
- AAPG is growing revenue fastest.
- AAPG keeps the most profit per dollar of sales.
- AAPG has been the calmest stock over the last 30 days.